Kornimate/medical-research-clean huggingface dataset:
creatine, d-ribose, b1 vitamin, and b6 vitamin in ischemic heart disease

Conditions: Ischemic Heart Disease

Summary: recently, researchers have paid attention to the development of new products such as supplements food and nutraceuticals for identify and develop integrative therapies to be used in cardiovascular disease. as suggested by literature, some nutritional components (creatine, ribose) can enhance the fundamental energy levels for the functioning of the heart muscle and can enhance the body's antioxidant capacity through the reduction in free radicals activity, one of the main pathogenic mechanisms of these diseases. in this context, the investigators have developed a research with the principal purpose to establish whether a supplement of creatine and ribose can improve the total work capacity during exercise in a population of patients with known ischemic heart disease.

the investigators will enroll patients with previous acute coronary syndrome treated for at least 30 days by hospital discharge. the treatment regimen of all patients will be optimized in accordance with european society of cardiology guidelines. standardized pharmacological treatment during cardiac rehabilitation period will include administration of angiotensin converting enzyme inhibition (ace), beta-blockers and antiplatelet blockers. furthermore, in order to keep patients free from angina symptoms, in some cases calcium channel blockers and/or nitrates will be used. the investigators will randomize participants into two groups, one receiving treatment creatine, d-ribose, b1 vitamin, and b6 vitamin, and one receiving placebo in a double blind study design, for 6 months.

Eligibility criteria:
inclusion criteria: * all patients presented acute coronary syndrome treated with at least 30 days by hospital discharge exclusion criteria: * oncological diseases * stable atrial fibrillation * stent in the common core * patients who are not able to perform physical activities * patients with documented sustained ventricular arrhythmias * pregnant women

Keywords: creatine, ribose, ischemic heart disease.
identifying modifiable patient centered therapeutics (impact) frailty

Conditions: Frailty; Sarcopenia

Summary: frailty, the decline in physical and cognitive reserves leading to vulnerability to stressors is increasingly being recognized as a public health concern. although multiple measures exist that can identify frail patients, very little is known about how or when to intervene. sarcopenia, or the degree of muscle wasting, is closely correlated to frailty and patient outcomes. this is a prospective cohort study of critically ill patients to identify modifiable risk factors of sarcopenia, as potential targets to reduce frailty.

frailty is the decline in physical and cognitive reserves leading to increased vulnerability to stressors such as surgery or disease states. frailty is not a disease, but a syndrome with a distinct frail phenotype that includes decreased status in mobility, muscle mass, nutritional status, strength, and endurance. frail patients are at greater risk of adverse outcomes, such as functional decline, prolonged hospitalization with associated increases in healthcare costs and death. multiple measures of frailty exist and although they are important for understanding risk for a given patient population or resource utilization, they do not provide any insight as to how to manage or treat frail patients. in critically ill patients, sarcopenia has long been tied to poor outcomes, poor nutrition status, and decreased ability to perform activities of daily living (adls). we hypothesize that sarcopenia as a marker for frailty in critically ill patients can be used to track development and recovery of frailty. the objective of this proposal to create a prospective cohort study of critically ill patients to identify modifiable risk factors of sarcopenia as potential targets for therapeutic measures to improve or reverse frailty. the primary aim of the study is to track sarcopenia in critically ill patients. sarcopenia is a measure of frailty and is associated with worse outcomes in critically ill patients. the aim to understand how the kinetics of sarcopenia differ in critically ill population given the heterogeneity of with various disease process which may affect the degree and rate of muscle wasting. understanding the disease process is important in identifying when or how to intervene to obtain meaningful recovery. secondary aims are to assess the role biomarkers in patients across the frailty spectrum to understand their role frailty. additionally nutrition is well known to affect sarcopenia and nutritional status is a key component in frailty. nutrition status will be tracked to understand development of sarcopenia.

Eligibility criteria:
inclusion criteria: * adult patients admitted to the surgical, cardiothoracic or neuro icu * icu stay longer than 24 hours exclusion criteria: * patients with muscular or mitochondrial diseases affecting muscle quality or mass * preexisting paralysis * absence of lower limbs * ongoing discussions about goals of care * transfers from a skilled nursing facility * children under the age of 18

Keywords: frailty sarcopenia ultrasound
impact of fingolimod adherence on outcomes

Conditions: Multiple Sclerosis

Summary: this study was a retrospective observational claims data study of commercial and medicare advantage with part d (mapd) patients initiating fingolimod.

the study sample comprised commercial and mapd enrollees who initiated fingolimod treatment during the identification period of 01 january 2012 through 10 may 2018. the date of the first fingolimod pharmacy claim during the identification period was the index date. all patients were continuously enrolled in the health plan for 24 months. the 6-month pre-index period, ending the day before the index date, was used to assess patients' clinical characteristics (e.g., comorbid conditions and ms symptoms). the 18-month post-index period started on the index date. the first 6 months of the post-index period (initiation period) were used to assess ms symptoms and adherence. months 7 - 18 of the post-index period (post-initiation period) were used to measure adherence and outcomes. the 24-month observation period for each patient comprised the 6-month pre-index and 18-month post-index periods.

Eligibility criteria:
inclusion criteria: * ≥18 years old during year of index date with valid gender and geographic information * continuous enrollment (ce) in the health plan with medical and pharmacy benefits for ≥6 months (180ii days) before the index date (pre-index period) * ce with medical and pharmacy benefits for ≥18 months (540 days) beginning on the index date (post-index period) * all patients had uniform 6-month pre-index and 18-month post-index periods * ≥1 medical claim with an ms diagnosis codei in any position during the pre-or post-index periods * ≥1 claim for fingolimod after the index date (i.e., from index date +1 to 539 days post-index) * by requiring ≥1 medical claim with an ms diagnosis code and ≥2 claims with an ndc for fingolimod, the inclusion criteria essentially incorporated the preferred/overall best performing ms case-finding definition validated by culpepper et al. the criteria for that definition required at least 3 separate encounters from any of the following: ms-related ambulatory visits, ms-related inpatient stays, and dmt claims during a 12-month period. slightly higher accuracy was found when a 24-month period was used. exclusion criteria: •≥1 pharmacy or medical claim for any ms dmt during the pre-index period
heterogeneity of neointimal healing following biodegradable-polymer drug-eluting coronary stent implantation

Conditions: Coronary Heart Disease; Stable Angina Pectoris; Silent Myocardial Ischemia

Summary: the objective of this study is a comparative evaluation of orsiro stent and of resolute integrity stent in terms of the extent of neointima formation at 4 months after implantation using optical coherence tomography (oct).

about 50 patients with clinical evidence of ischemic heart disease and / or a positive functional study and documented stable angina pectoris (canadian cardiovascular society classification (ccs)1, 2, 3 or 4), or documented silent ischemia in de-novo, native, previously unstented vessel in tyumen cardiology center,will be randomly assigned undergoing implantation of orsiro stent or resolute integrity stent (in a 1:1 ratio). all of the patients will receive 12 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 1 year. the follow-up visits will be conducted at 4 months (including angiographic/oct investigation), and 1 year post percutaneous coronary intervention(pci),in order to observe the primary endpoint and secondary endpoints.

Eligibility criteria:
inclusion criteria: * age \> 18 years; * patients with symptoms of stable angina and/or presence of a positive functional test for ischemia; * patient is eligible for percutaneous coronary intervention (pci); * patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the ethical committee of the respective clinical site. exclusion criteria: * target lesion involving a bifurcation with a side branch ≥2.0 mm in diameter; * target lesion located in the left main stem; * target lesion is located or supplied by an arterial or venous bypass graft; * lesion located very distally, difficult to be imaged by oct; * co-morbidities that could interfere with completion of study procedures, or life expectancy less than 1 year; * participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study; * patient underwent target vessel revascularization with a des; * patient presenting with acute myocardial infarction with st elevation; * cerebrovascular accident within the past 12 months; * acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl); * patient receiving oral anticoagulants
evaluating the effect of tooth cleaning devices on oral health

Conditions: Dental Plaque

Summary: this is a study to evaluate the safety and the efficacy of tooth and interproximal cleaning modalities on oral health.


Eligibility criteria:
inclusion criteria: * are in good/excellent health; * are 18 - 70 years old; * have a minimum of 20 natural teeth (excluding 3rd molars); * have sufficient test sites; * have ≥ 20 bleeding sites; * are willing to participate and available for participation. exclusion criteria: * have systemic diseases such as down's syndrome, or known aids/hiv; * have insulin dependant diabetes; * are pregnant or nursing by subject report; * have a cardiac pacemaker * are undergoing or require extensive dental or orthodontic treatment; * require antibiotic treatment for dental appointments; * have heavy deposits of calculus; * have severe gingivitis or periodontitis; * have extensive crown or bridge work and/or rampant decay; * currently use bleaching trays; * have any oral or extraoral piercing on lips or in mouth; * have a professional prophylaxis within 4 weeks of study; * participation in a prior study ≤ 20 days; * employed by a oral healthcare products company or research institution.

Keywords: dental dentist plaque ip cleaning
growth hormone treatment in infants aged 1 to 2 years with chronic renal insufficiency (cri) and growth retardation.

Conditions: Chronic Kidney Disease; Chronic Renal Insufficiency

Summary: this trial is conducted in europe. objective(s): to evaluate the effect of human growth hormone on infants aged 1 to 2 years with chronic renal insufficiency (cri) and growth retardation despite an adequate dietary intake. trial design: this is an open, parallel group clinical trial with a duration of one year, in which period 50% of patients will receive gh treatment and the other 50% will act as a control group, without treatment. trial population: the trial will involve a total of 16 infants aged from 12±3 to 24 months suffering chronic renal insufficiency (glomerular filtration rate less than 60 ml/min/1.73 m2), and growth failure and undergoing conservative treatment or peritoneal dialysis. include the key inclusion and exclusion criteria.


Eligibility criteria:
inclusion criteria: * patients will be infants of both sexes aged 12 ± 3 months with chronic renal insufficiency and growth retardation. * to be included in the trial, patients must meet all of the following inclusion criteria a.)-c.): * a.) male or female infants with a chronological age of 12 ± 3 months * b.) chronic renal insufficiency with glomerular filtration rate less than 60 ml/min./1.73m2, according to the method used routinely in each participating center * c.) growth retardation documented at the start of the trial, according to the following criteria: length less than -2 sds by chronological age and sex and linear growth velocity \<p50 according to the hernández standards and to lubchenko in the case of infants born prematurely (\<37 weeks) * conservative treatment or chronic peritoneal dialysis * euthyroid * the parent or guardian must give informed consent to the child's participation in the study before any trial related activities. trial related activities are any procedures that would not have been performed during the normal management of the subject * optimal nutritional management criteria met * appropriate metabolic control for severe hyperparathyroidism, hydroelectrolyte balance, acid-base balance and calcium-phosphorus balance exclusion criteria: * any primary endocrinological disorder and severe renal osteodystrophy.other causes, apart from cri, giving rise to growth retardation.hydrocephalus. * known or suspected allergy to the trial product or related products. * treatment with corticosteroids within the last six months. * renal disease due to the fanconi syndrome or to oxalosis (except if not under dialysis). * known or suspected malignancy.
the effects of time-restricted eating model

Conditions: Time Restricted Feeding; Feeding Behavior; Impulsive Behavior

Summary: there is increasing evidence of the effects of the time-restricted diet model based on the daily intake of energy within a period of 8-12 hours on body weight control and metabolic parameters. there is no study on the potential effects of this nutritional model, which is thought to be an effective strategy in struggling with metabolic syndrome, on individuals' eating behavior and impulsivity levels. this study, which aims to evaluate the effects of time- restricted diet strategy on food intake, eating attitude and behavior and impulsivity level in adults, is a mixed method, randomized controlled intervention study. thirty adult individuals between the ages of 18-65 will be included in this study, which will be carried out between 31.05.2021-31.12.2021 in istinye university. participants will be divided into 2 groups: the intervention group (n = 15) will apply a time-restricted nutrition model for 4 weeks, and no intervention will be applied to the control group (n = 15). participants' food intake before and after the intervention period will be evaluated with a 3-day food intake record, their eating attitudes will be evaluated with the eating attitude test (eat-26), their impulsivity levels will be evaluated with the barratt impulsiveness scale-short form (bis-11-sf) and go / nogo test, and their eating behaviors will be evaluated with the three factor eating questionnaire (tfeq-r21). at the end of the research, all individuals in the intervention group will be interviewed in depth and their experiences regarding the process will be recorded. ibm spss 22 program will be used in the analysis of all quantitative data, and the maxqda-12 program will be used in the analysis of qualitative data. the data obtained from this research will clear up the applicability of the time- restricted diet model and its effects on eating behaviors of adults.


Eligibility criteria:
inclusion criteria: * being between the ages of 18-65, * body mass index (bmi) ≥ 18.5 kg/m2, * routine eating window ≥10 hours (including all energy-containing meals and drinks), * to agree to participate in the research voluntarily. exclusion criteria: * age \ 65, * bmi \<18.5 kg/m2, * to have applied nutritional therapy for weight loss or medical treatment in the last 6 months, * being in pregnancy or lactation period, * working the night shift or the partner working the night shift (if it affects the participant's sleep and nutritional status), * having a known neurological or psychological disorder, * declaring that have a history of eating disorder in the last 3 months, * weight change of ≥ 5 kg in the last 3 months, * having an uncontrolled medical problem (cardiovascular, pulmonary, rheumatological, hematological, oncological, gastrointestinal, psychiatric, endocrinological, etc.) * receiving medical treatment that may have a significant impact on glucose metabolism, appetite or energy balance, * being on antidepressant treatment, * having a history of bariatric surgery, * having celiac, crohn's or ulcerative colitis.
effectiveness of an electronic decision support system (dessback) in improving the management of low back pain

Conditions: Lower Back Pain

Summary: low back pain is a common health problem where over than half a billion people worldwide suffers from it. in malaysia, back pain is among the top ten reasons why people see a doctor. although there are many guidelines available, healthcare professionals still find managing low back pain as challenging. the decision support system for low back pain (dessback) has been developed by adopting and re-packaging start system, incorporate with the local clinical practice guidelines and feedback from local experts. it aims to aid healthcare professionals in managing low back pain through a stratified approach. the objective of the study is to evaluate the effectiveness of dessback in improving the management of patients with low back pain in a primary care clinic. we hypothesise that the implementation of dessback will improve the outcomes of low back pain patients including quality of life, emotional state and level of pain. this study protocol presents the rationale and design of a cluster randomized controlled trial.


Eligibility criteria:
inclusion criteria: * patient seeking care for low back pain at the primary care clinic in ummc * male and female * age 18 years and above * can understand malay and english exclusion criteria: * potentially serious pathology (eg: cauda equina compression, inflammatory arthritis, malignancy and etc) * serious co morbidity * psychiatric illness or personality disorder * spinal surgery in the last 6 months * pregnant * already receiving treatment other than primary care for this episode of back pain * inability to attend regular physiotherapy appointments.
saw palmetto: symptom management for men during radiation therapy

Conditions: Prostate Cancer

Summary: the aim of this study is to test whether saw palmetto, is useful in preventing or reducing the side effects for men undergoing radiation therapy for prostate cancer. urinary symptoms will be recorded each week, as well as assessment of quality of life through: 1) physical well-being 2) social/family well-being 3) emotional well-being, and 4) functional well-being.

lower urinary tract symptoms (luts) affect from 75-80% of men undergoing radiation therapy (rt) for prostate cancer. the purpose of this study was to determine the feasibility, safety and efficacy of inexpensive, non-toxic herbal supplement, saw palmetto (sp), in treating these distressing symptoms. the study consisted of two phases: dose finding phase (dfp), and exploratory randomized controlled trail (rct) phase. in the 12 week dfp, participants were given one of three doses (sp 320 mg, sp 640mg, and sp 960 mg) using the time-to-event continual reassessment method to determine the maximum therapeutic dose (mtd). once the mtd was determined the rct phase was begun, participants were allocated to receive either the predetermined mtd (960 mg) in the dfp or a placebo to obtain preliminary evidence of efficacy of sp on luts. safety data consisted of the common terminology for adverse events criteria for nausea, gastritis, and anorexia. efficacy of the mtd was evaluated by weekly symptom data and voiding diary. a pill diary was used to ensure the intervention fidelity.

Eligibility criteria:
inclusion criteria: * age 21 years or older * adenocarcinoma of the prostate * serum prostate specific antigent (psa) ≤ 40ng/ml * combined gleason score ≤ 8 * karnofsky level of performance of \> 70% * consented to undergo definitive radiation therapy exclusion criteria: * stage t4 or m1 * patient using own supply of saw palmetto or any other supplement containing the following herbs: pygeum (african plum), urtica dioica (stinging nettle), cucurbita peponis (pumpkin seed), pc-spes (combination of 8 herbs), beta-sitsterol (plant sterols) or cernilton (rye grass pollen). * prior pelvic radiation therapy * abnormality in liver and kidney function as evidenced by greater than twice the normal values of blood urea nitrogen (bun), serum creatine, serum transaminases, and alkaline phosphatase. * uncontrolled hypertension despite use of antihypertensive medication * presence of major psychiatric or medical illness (e.g., major cardiovascular events within the previous 12 months)

Keywords: prostate cancer radiation therapy quality of life symptom management